Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Assessing Anthracycline Cardiotoxicity In The 1990s

I. Carrió, M. Estorch, A. López-Pousa
Published 2005 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Anthracycline cardiotoxicity is caused by stimulated reactive oxygen metabolism. Augmented reactive oxygen flux, mediated by free radicals, causes myocyte cell damage at specific sites. In addition, anthracyclines or their metabolites may trigger release of endogenous substances such as histamine, arachidonic acid metabolites, platelet-activating factor, calcium and other compounds potentially deleterious to the myocardium [1-4]. From a clinical point of view, acute cardiotoxicity following a single anthracycline dose appears different from the chronic cardiomyopathy resulting from cumulative anthracycline administration [5-7]. Acute toxicity is often subclinical with acute and reversible electrocardiographic changes without clinical evidence of myocardial dysfunction. This can be observed in about 30% of patients within hours of doxorubicin infusion. Exceptionally, acute cardiotoxicity may present after a single dose of doxorubicin as pancarditis with overt biventricular failure. More meaningfully from a clinical viewpoint, chronic anthracycline cardiomyopathy is a congestive cardiomyopathy characterized by a non-dilated tachycardic heart with low output secondary to progressive hypocontractility which is usually unresponsive to cardiotonic agents. Chronic cardiomyopathy, unlike acute cardiomyopathy, has a delayed clinical expression, this expression occurring weeks or months after the last doxorubicin dose. Cardiotoxicity presenting well after chemotherapy had not been seriously considered until recent reports indicated an unexpectedly high incidence of late permanent cardiac functional abnormalities in patients with prolonged survival [8, 9]. More than half of children with acute lymphoblastic leukaemia in whom complete clinical remission is induced by anthracycline-containing chemotherapy may have abnormalities in contractility or in ventricular wall thickness many years after completion of therapy [8]. Prevention of this type of late cardiotoxicity in long-term survivors poses a new challenge to all medical professions involved in cancer treatment. The merely functional definition of cardiotoxicity has, of course, several drawbacks. Functional impairment is a consequence of myocardial cell damage caused by administration of the drug. Therefore, using a purely functional approach, cell damage below this threshold is not considered as cardiotoxicity. In addition, other neurohumoral factors besides myocyte cell damage may contribute to deterioration of function. Alteration of these neurohumoral mechanisms may also precede functional impairment and is part of the spectrum of cardiotoxic effects of anthracycline administration [10]. The definition of cardiotoxicity therefore has to be reviewed in the light of our improved knowledge of the natural history of the disease, and of the pathophysiological and neurohumoral interactions which result in this complex cardiomyopathy. Understanding of the underlying tissular mechanisms at a molecular level should lead to earlier diagnosis and facilitate the prevention of long-term deleterious effects.
This paper references
Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.
A. Avilés (1993)
Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.
L. Steinherz (1992)
Cardiac morphologic and functional changes induced by epirubicin chemotherapy.
M. Dardir (1989)
Noninvasive identification of anthracycline cardiotoxicity: Comparison of123I-MIBG and123I-BMIPP imaging
Y. Takeishi (1994)
Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection.
M. K. Ali (1994)
In-vivo and in-vitro mitochondrial membrane damages induced in mice by adriamycin and derivatives.
M. Praet (1993)
Pilot study of cardiac function after treatment of childhood Wilms' tumor with doxorubicin.
J. Blatt (1995)
Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
J. Speyer (1988)
Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease.
S. Mortensen (1986)
Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy.
R. V. Valdés Olmos (1995)
Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
I. Carrio (1993)
Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
J. Alexander (1979)
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
Adriamycin, congestive cardiomyopathy, and metaiodobenzylguanidine.
A. Strashun (1992)
Detection of Adriamycin-induced cardiotoxicity in cultured heart cells with technetium 99m-SESTAMIBI
D. Piwnica-Worms (2004)
I‐123 MIBG and Serial Radionuclide Angiocardiography in Doxorubicin‐related Cardiotoxicity
R. V. Valdés Olmos (1992)
Ewing's sarcoma: long-term follow-up in 49 patients treated from 1967 to 1989.
H. Mameghan (1993)
Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography.
S. Palmeri (1986)
Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity.
M. Druck (1984)
Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity.
I. Carrio (1995)
Constant infusion schedule for adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system.
J. Lokich (1983)
Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.
S. Wakasugi (1992)
Myocarditis associated with doxorubicin cardiotoxicity.
P. B. Gaudin (1993)
Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases.
J. Saini (1987)
Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans.
M. Stoddard (1992)
Monitoring for anthracycline cardiotoxicity.
S. Lipshultz (1994)
Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies
I. Carrió (2004)
Effects of bone marrow transplantation on myocardial function in children.
J. Pihkala (1994)
IHIn - antimyosin and 123 I - MIBG studies in the early assessment of doxorubicin cardiotoxicity
I Carri6 (1995)
Detection of Early Anthracycline Cardiotoxicity by Monitoring the Peak Filling Rate
W. Ganz (1993)
Assessment of anthracycline - related myocardial adrenergic derangement by ~ 23 I - MIBG scintigraphy
RA Vald6sOlmos (1995)
[Noninvasive evaluation of chronic cumulative and acute cardiotoxicity induced by anthracycline in children with acute leukemia. Assessment of mainly left ventricular contractile state by M mode echocardiography].
S. Nakada (1994)
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
S. Lipshultz (1991)
Alterations in left ventricular diastolic function with doxorubicin therapy.
B. H. Lee (1987)
Usefulness of indium-111 antimyosin scintigraphy in confirming myocardial injury in patients with anthracycline-associated left ventricular dysfunction.
R. V. Valdés Olmos (1994)
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients.
L. Steinherz (1995)
Late doxorubicin‐associated cardiotoxicity in children
M. Ali (1994)
Antimyosin positivity in doxorubicin cardiotoxicity: earlier than the conventional evidence.
J. Narula (1993)
Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer.
M. Estorch (1990)
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.
M. Ewer (1984)
Indium - lll - antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer
M Estorch (1990)
Acute effects of adriamycin on the macromolecular organization of the cardiac muscle cell plasma membrane.
N. Severs (1991)
Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity.
S. Rajagopalan (1988)
Usefulness of indium - Il l antimyosin scintigraphy in confirming myocardial injury in patients with anthracycline - associated left ventricular dysfunction
R Vald6s-Olmos (1994)
Subclinical cardiotoxicity by doxorubicin: a pulsed Doppler echocardiographic study.
A. Cittadini (1991)
Scintigraphic evaluation of myocardial uptake of thallium 201 and technetium 99m pyrophosphate utilizing a rat model of chronic doxorubicin cardiotoxicity
M. Miyagawa (2005)
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
R. G. Schwartz (1987)
Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: results of two sequential studies.
G. Bacci (1993)
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
S. Legha (1982)
Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy.
S. Wakasugi (1993)

This paper is referenced by
Toxische Schäden des Herzens durch Alkohol, Anthrazykline und Kokain
H. Frenzel (2000)
Kardiomiopatia poantracyklinowa - diagnostyka, leczenie i zapobieganie
I. Pietka (2010)
Nuclear medicine in tailoring treatment in oncology.
R. V. Valdés Olmos (2001)
The Use of Cardiac Biomarkers to Detect Myocardial Damage Induced by Chemotherapeutic Agents
E. Herman (2003)
Age and left ventricular ejection fraction identify patients with advanced breast cancer at high risk for development of epirubicin-induced heart failure
B. Schaadt (1997)
Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.
J. Bertinchant (2003)
Diagnostyka uszkodzeń i dysfunkcji mięśnia sercowego wywołanych antracyklinami The diagnosis of anthracycline-induced cardiac damage and heart failure
F. Burdan (2009)
Estrategias de prevención de cardiotoxicidad Preventive strategies of cardiotoxicity
Eduardo Meaney (2016)
Word count : 3504 Tables : — Figures : — References : 120 Adres autora :
J. Dudka (2009)
Nuclear medicine diagnostic tools for early detection of myocardial damage in treated breast cancer patients
A. Tzonevska (2014)
Drug-induced heart failure.
J. Feenstra (1999)
Detection of radiation-induced myocardial damage by technetium-99m sestamibi scintigraphy
G. Gyenes (2005)
GSPECT-CT myocardial scintigraphy plus calcium scores as screening tool for prevention of cardiac side effects in leftsided breast cancer radiotherapy.
A. Tzonevska (2014)
Semantic Scholar Logo Some data provided by SemanticScholar